Mary Padbury, Katherine Bach Kalin
Clinical Genomics announced the appointments of Mary Padbury and Katherine Bach Kalin to its board. Padbury, who will be the chairman of the board, has done intellectual property work for Australian and multinational companies. She was most recently a partner and vice chairman of law firm Ashurst. She currently is chairman of the board for Trans-Tasman IP Attorneys.
Kalin has more than 25 years of experience as a senior executive in the healthcare and professional services industries. Most recently, she led corporate strategy at Celgene. Prior to her role at Celgene, Kalin held leadership roles in marketing, sales, strategy, and new business development at Johnson & Johnson.
Daniel Kolk has joined XCR Diagnostics as VP of clinical development. He previously served as senior director of product development for Hologic, where he led development and US Food and Drug Administration clearance of respiratory assays on Hologic's Panther Fusion system. Prior to this he helped develop human papillomavirus and blood screening products at Gen-Probe, which was acquired by Hologic.
Asuragen has hired Tom Copa as its SVP, commercial operations. Copa will lead the global sales, marketing, and customer solutions teams for the firm's diagnostics products business. Prior to Asuragen, Copa served as VP of licensed technologies at Luminex, as well as spending over 16 years as a senior executive in several roles at the firm.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.